Prof. Michal Lotem
Michal Lotem, MD received her MD degree from Tel Aviv University School of Medicine; Board Certification in Dermatology (1993) and Clinical and Radiation Oncology (1997) following residency in Hadassah Hebrew Universi Hospital. Did a post-doctoral research fellowship with Dr. Steven Rosenberg, Chief, Surgery Branch, NCI, Bethesda, Md, US (2002-2004) .
Dr. Michal Lotem is an active cancer immunotherapist, combining clinical work with scientific translational research. In the clinic, Dr. Lotem participated in pivotal trials that led to FDA’s approval of CTLA-4 and PD1 inhibitors for metastatic melanoma. The Lotem Lab worked in the past on vaccines made of autologous or engineered cancer cells, and adoptive cell therapy of tumor infiltrating lymphocytes (TILs). Currently, the Lab is preparing a clinical grade TCR-T cells cognate of cancer-testis antigen NY-ESO-1.
In basic research, the Lab is studying the SLAM family of immune receptors, with emphasis on the regulatory effect of alternative splicing.
Dr. Lotem’s belief is that researcher-clinicians should be the motivating force behind scientific research to enhance and advance cancer cure.